ReviewEBioMedicine2021
Engineering mammalian living materials towards clinically relevant therapeutics.
Review in EBioMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
- Modeling cancer with bacteria-integrated tumor microenvironments using biomaterials: Emerging concepts and opportunities.Materials today. Bio · 2026Review
- Bioinspired and living multiscale composites for regenerative medicine in the treatment of surgical site infections.Journal of nanobiotechnology · 2026Review
- Gradients of Aliveness and Engineering: A Taxonomy of Fungal Engineered Living Materials.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- The Challenge of the Yuck Factor in Public Acceptance of Engineered Living Materials.Global challenges (Hoboken, NJ) · 2025Article
- Advances in abiotic tissue-based biomaterials: A focus on decellularization and devitalization techniques.Materials today. Bio · 2025Article
- Designer mammalian living materials through genetic engineering.Bioactive materials · 2025Review
- Engineered nascent living human tissues with unit programmability.Nature materials · 2025Article
- Cell Surface Engineering Tools for Programming Living Assemblies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Scalable fabrication, compartmentalization and applications of living microtissues.Bioactive materials · 2023Article
- Close-to-native bone repair via tissue-engineered endochondral ossification approaches.iScience · 2022Review
- Health horizons: Future trends and technologies from the European Medicines Agency's horizon scanning collaborations.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engineered living materials represent a new generation of human-made biotherapeutics that are highly attractive for a myriad of medical applications. In essence, such cell-rich platforms provide encodable bioactivities with extended lifetimes and environmental multi-adaptability currently unattainable in conventional biomaterial platforms. Emerging cell bioengineering tools are herein discussed from the perspective of materializing living cells as cooperative building blocks that drive the assembly of multiscale living materials. Owing to their living character, pristine cellular units can also be imparted with additional therapeutically-relevant biofunctionalities. On this focus, the most recent advances on the engineering of mammalian living materials and their biomedical applications are herein outlined, alongside with a critical perspective on major roadblocks hindering their realistic clinical translation. All in all, transposing the concept of leveraging living materials as autologous tissue-building entities and/or self-regulated biotherapeutics opens new realms for improving precision and personalized medicine strategies in the foreseeable future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.